Vericel Corp Files 8-K: Matters for Vote & Financials
Ticker: VCEL · Form: 8-K · Filed: May 3, 2024 · CIK: 887359
Sentiment: neutral
Topics: corporate-governance, financial-reporting
Related Tickers: VCEL
TL;DR
VCEL filed an 8-K for shareholder votes and financials - check for details.
AI Summary
On May 1, 2024, Vericel Corporation filed an 8-K report detailing a submission of matters to a vote of security holders and financial statements and exhibits. The filing does not contain specific financial figures or details about the matters to be voted on, but it indicates a formal reporting event for the company.
Why It Matters
This 8-K filing signals important corporate actions, including potential shareholder votes and the release of financial information, which are crucial for investors to assess the company's performance and governance.
Risk Assessment
Risk Level: low — This filing is a routine procedural report and does not disclose new material financial information or significant operational changes that would inherently increase risk.
Key Players & Entities
- Vericel Corporation (company) — Registrant
- May 1, 2024 (date) — Date of Earliest Event Reported
- Michigan (jurisdiction) — State of Incorporation
- 001-35280 (identifier) — Commission File Number
- 94-3096597 (identifier) — I.R.S. Employer Identification No.
- 64 Sidney Street, Cambridge, MA 02139 (address) — Principal Executive Offices
- 617-588-5555 (phone_number) — Registrant's telephone number
- AASTROM BIOSCIENCES INC (company) — Former Company Name
- 19960428 (date) — Date of Name Change
FAQ
What specific matters are being submitted for a vote of Vericel Corporation's security holders?
The filing indicates that matters are being submitted for a vote, but it does not specify what those matters are. Further details would typically be found in subsequent filings or proxy statements.
What financial statements and exhibits are included in this 8-K filing?
The filing states that 'Financial Statements and Exhibits' are included, but the specific content of these statements and exhibits is not detailed within the provided text.
When was the earliest event reported in this Form 8-K?
The earliest event reported in this Form 8-K was on May 1, 2024.
What is Vericel Corporation's principal executive office address?
Vericel Corporation's principal executive office is located at 64 Sidney Street, Cambridge, MA 02139.
Has Vericel Corporation changed its name previously?
Yes, Vericel Corporation was formerly known as AASTROM BIOSCIENCES INC, with the name change occurring on April 28, 1996.
Filing Stats: 827 words · 3 min read · ~3 pages · Grade level 15.8 · Accepted 2024-05-03 16:05:33
Filing Documents
- ef20028422_8k.htm (8-K) — 52KB
- 0001140361-24-024327.txt ( ) — 185KB
- vcel-20240501.xsd (EX-101.SCH) — 4KB
- vcel-20240501_lab.xml (EX-101.LAB) — 21KB
- vcel-20240501_pre.xml (EX-101.PRE) — 16KB
- ef20028422_8k_htm.xml (XML) — 4KB
07
Item 5.07 Submission of Matters to a Vote of Security Holders. At the Company's Annual Meeting of Shareholders held on May 1, 2024 (the "Annual Meeting") , the shareholders of the Company voted on the following matters, which are described in detail in the Company's Definitive Proxy Statement filed with the Securities and Exchange Commission ("SEC") on March 21, 2024: (i) the election of each of Robert Zerbe, Alan Rubino, Heidi Hagen, Steven Gilman, Kevin McLaughlin, Paul Wotton, Lisa Wright and Dominick Colangelo as a director of the Company to serve for a one-year term expiring at the Company's 2025 annual meeting of shareholders and until his or her successor has been elected and qualified ("Proposal 1"), (ii) the approval, on a non-binding advisory basis, of the compensation of the named executive officers of the Company ("Proposal 2"), (iii) the frequency of future advisory votes to approve the compensation of our named executive officers ("Proposal 3") and (iv) the ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 ("Proposal 4"). The Company's shareholders approved the nominees recommended for election in Proposal 1 at the Annual Meeting. Shareholders voted for directors as follows: Nominee For Abstain/Withheld Broker Non-Votes Robert Zerbe 41,278,370 2,004,339 2,202,810 Alan Rubino 41,205,989 2,076,720 2,202,810 Heidi Hagen 35,218,337 8,064,372 2,202,810 Steven Gilman 42,205,350 1,077,359 2,202,810 Kevin McLaughlin 42,263,852 1,018,857 2,202,810 Paul Wotton 40,144,951 3,137,758 2,202,810 Lisa Wright 40,724,522 2,558,187 2,202,810 Dominick Colangelo 42,041,793 1,240,916 2,202,810 The Company's shareholders approved, on a non-binding advisory basis, Proposal 2 concerning the compensation of the Company's named executive officers. The votes cast at the Annual Meeting were as follows: Votes For Votes
executive compensation
executive compensation. The Company's shareholders approved Proposal 4 to ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered accounting firm for the fiscal year ending December 31, 2024. The votes cast at the Annual Meeting were as follows: Votes For Votes Against Abstentions 43,592,984 1,867,944 24,591
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL) EXHIBIT INDEX Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Vericel Corporation Date: May 3, 2024 By: /s/ Sean C. Flynn Name: Sean C. Flynn Title: Chief Legal Officer